These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 17947225

  • 1. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
    Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M.
    Ann Oncol; 2008 Feb; 19(2):362-9. PubMed ID: 17947225
    [Abstract] [Full Text] [Related]

  • 2. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
    Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U, FLEX Study Team.
    Lancet; 2009 May 02; 373(9674):1525-31. PubMed ID: 19410716
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL, ADJUVANT investigators.
    Lancet Oncol; 2018 Jan 02; 19(1):139-148. PubMed ID: 29174310
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D, Zheng X, Chen J, Liu G, Xu Y, Shen Y, Xie L, Zhao W, Jiang G, Fan M.
    Lung Cancer; 2015 Sep 02; 89(3):249-54. PubMed ID: 26118463
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
    Clark JI, Kancharla K, Qamar R, Fisher S, Hantel A, Panganiban J, Millbrandt L, Albain KS.
    Lung Cancer; 2001 Nov 02; 34(2):271-7. PubMed ID: 11679186
    [Abstract] [Full Text] [Related]

  • 9. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
    Gebbia V, Galetta D, Riccardi F, Gridelli C, Durini E, Borsellino N, Gebbia N, Valdesi M, Caruso M, Valenza R, Pezzella G, Colucci G, Gruppo Oncologico Italia Meridionale.
    Lung Cancer; 2002 Aug 02; 37(2):179-87. PubMed ID: 12140141
    [Abstract] [Full Text] [Related]

  • 10. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA, SQUIRE Investigators.
    Lancet Oncol; 2015 Jul 02; 16(7):763-74. PubMed ID: 26045340
    [Abstract] [Full Text] [Related]

  • 11. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
    Colucci G, Gebbia V, Galetta D, Riccardi F, Cariello S, Gebbia N.
    Br J Cancer; 1997 Jul 02; 76(11):1509-17. PubMed ID: 9400950
    [Abstract] [Full Text] [Related]

  • 12. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients.
    Souquet PJ, Tan EH, Rodrigues Pereira J, Van Klaveren R, Price A, Gatzemeier U, Jaworski M, Burillon JP, Aubert D.
    Ann Oncol; 2002 Dec 02; 13(12):1853-61. PubMed ID: 12453852
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L.
    Lung Cancer; 2004 Oct 02; 46(1):87-98. PubMed ID: 15364136
    [Abstract] [Full Text] [Related]

  • 18. A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.
    Dingemans AM, Bootsma G, van Baardwijk A, Reymen B, Wanders R, Brans B, Das M, Hochstenbag M, van Belle A, Houben R, Lambin P, de Ruysscher D.
    J Thorac Oncol; 2014 May 02; 9(5):710-6. PubMed ID: 24722157
    [Abstract] [Full Text] [Related]

  • 19. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
    Douillard JY, Gervais R, Dabouis G, Le Groumellec A, D'Arlhac M, Spaeth D, Coudert B, Caillaud D, Monnier A, Clary C, Maury B, Mornet M, Rivière A, Clouet P, Couteau C.
    Ann Oncol; 2005 Jan 02; 16(1):81-9. PubMed ID: 15598943
    [Abstract] [Full Text] [Related]

  • 20. Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC).
    Reinmuth N, Meyer A, Hartwigsen D, Schaeper C, Huebner G, Skock-Lober R, Bier A, Gerecke U, Held CP, Reck M.
    Lung Cancer; 2014 Mar 02; 83(3):363-8. PubMed ID: 24462464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.